Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Adaptive Biotechnologies Corp (ADPT) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Adaptive Biotechnologies Corp. Table 2 shows the detailed insider transactions. This company's CIK number is 1478320.
Total stock buying since 2019: $15,244,000.
Total stock sales since 2019: $1,191,021,204.
Total stock option exercises since 2019: $36,672,527.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 2,345,234 | $19,039,812 | 1,818,901 | $11,382,947 |
| 2024 | 0 | $0 | 208,558 | $747,749 | 20,000 | $22,500 |
| 2023 | 0 | $0 | 371,811 | $3,040,391 | 302,289 | $1,197,659 |
| 2022 | 0 | $0 | 149,445 | $1,629,238 | 44,445 | $280,890 |
| 2021 | 0 | $0 | 2,680,192 | $137,995,448 | 1,682,742 | $12,377,740 |
| 2020 | 0 | $0 | 28,716,845 | $1,018,663,741 | 3,163,148 | $11,125,841 |
| 2019 | 762,200 | $15,244,000 | 335,000 | $9,904,825 | 375,000 | $284,950 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 0 | $0 | 70,341 | $519,976 | 68,412 | $432,363 |
| 2025-03 | 0 | $0 | 578,602 | $4,151,878 | 54,198 | $230,031 |
| 2025-02 | 0 | $0 | 1,696,291 | $14,367,958 | 1,696,291 | $10,720,553 |
| 2024-11 | 0 | $0 | 248 | $1,235 | 0 | $0 |
| 2024-10 | 0 | $0 | 0 | $0 | 5,000 | $9,900 |
| 2024-08 | 0 | $0 | 26,922 | $121,068 | 0 | $0 |
| 2024-03 | 0 | $0 | 181,388 | $625,446 | 15,000 | $12,600 |
| 2023-12 | 0 | $0 | 0 | $0 | 100,000 | $84,000 |
| 2023-11 | 0 | $0 | 259 | $1,069 | 0 | $0 |
| 2023-08 | 0 | $0 | 16,202 | $107,317 | 0 | $0 |
| 2023-06 | 0 | $0 | 242,961 | $1,967,762 | 149,289 | $1,089,809 |
| 2023-04 | 0 | $0 | 3,125 | $26,862 | 0 | $0 |
| 2023-03 | 0 | $0 | 106,139 | $910,649 | 0 | $0 |
| 2023-02 | 0 | $0 | 0 | $0 | 53,000 | $23,850 |
| 2023-01 | 0 | $0 | 3,125 | $26,732 | 0 | $0 |
| 2022-11 | 0 | $0 | 32,025 | $257,034 | 0 | $0 |
| 2022-10 | 0 | $0 | 3,125 | $22,684 | 0 | $0 |
| 2022-08 | 0 | $0 | 17,540 | $192,589 | 0 | $0 |
| 2022-07 | 0 | $0 | 3,125 | $31,943 | 0 | $0 |
| 2022-04 | 0 | $0 | 831 | $10,944 | 0 | $0 |
| 2022-03 | 0 | $0 | 91,778 | $1,090,235 | 44,445 | $280,890 |
| 2022-01 | 0 | $0 | 1,021 | $23,809 | 0 | $0 |
| 2021-12 | 0 | $0 | 25,338 | $760,140 | 25,338 | $182,750 |
| 2021-11 | 0 | $0 | 14,000 | $477,792 | 14,000 | $98,900 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-16 | Piskel Kyle (Chief Financial Officer) | Sale | 1,929 | 8.89 | 17,148 |
| 2025-05-01 | Robins Harlan S (Chief Scientific Officer) | Sale | 68,412 | 7.35 | 502,828 |
| 2025-05-01 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 68,412 | 6.32 | 432,363 |
| 2025-03-24 | Robins Harlan S (Chief Scientific Officer) | Sale | 1,698 | 9.00 | 15,282 |
| 2025-03-24 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 1,698 | 6.32 | 10,731 |
| 2025-03-14 | Piskel Kyle (Chief Financial Officer) | Option Ex | 2,500 | 6.32 | 15,800 |
| 2025-03-13 | Griffin Michelle Renee (Director) | Sale | 36,291 | 7.19 | 260,932 |
| 2025-03-12 | Hershberg Robert (Director) | Sale | 53,000 | 7.59 | 402,270 |
| 2025-03-10 | Neupert Peter M (Director) | Sale | 10,000 | 7.05 | 70,500 |
| 2025-03-10 | Neupert Peter M (Director) | Option Ex | 50,000 | 4.07 | 203,500 |
| 2025-03-06 | Robins Chad M (CEO and Chairman) | Sale | 102,218 | 7.64 | 780,945 |
| 2025-03-05 | Bobulsky Susan (Chief Commercial Officer, MRD) | Sale | 26,023 | 6.98 | 181,640 |
| 2025-03-05 | Benzeno Sharon (Chief Commercial Ofc Imm Med) | Sale | 44,665 | 6.99 | 311,985 |
| 2025-03-05 | Robins Harlan S (Chief Scientific Officer) | Sale | 96,656 | 6.99 | 675,142 |
| 2025-03-05 | Rubinstein Julie (President and COO) | Sale | 59,505 | 6.99 | 415,642 |
| 2025-03-05 | Piskel Kyle (Chief Financial Officer) | Sale | 10,320 | 6.98 | 72,033 |
| 2025-03-05 | Lo Francis (Chief People Officer) | Sale | 20,875 | 6.99 | 145,811 |
| 2025-03-05 | Robins Chad M (CEO and Chairman) | Sale | 117,351 | 6.99 | 819,696 |
| 2025-02-20 | Robins Chad M (CEO and Chairman) | Sale | 99,107 | 8.44 | 836,463 |
| 2025-02-20 | Robins Chad M (CEO and Chairman) | Option Ex | 99,107 | 6.32 | 626,356 |
| 2025-02-19 | Robins Chad M (CEO and Chairman) | Sale | 186,080 | 8.46 | 1,574,236 |
| 2025-02-19 | Robins Chad M (CEO and Chairman) | Option Ex | 186,080 | 6.32 | 1,176,025 |
| 2025-02-18 | Robins Chad M (CEO and Chairman) | Sale | 422,320 | 8.50 | 3,589,720 |
| 2025-02-18 | Robins Chad M (CEO and Chairman) | Option Ex | 422,320 | 6.32 | 2,669,062 |
| 2025-02-14 | Robins Chad M (CEO and Chairman) | Sale | 317,842 | 8.46 | 2,688,942 |
| 2025-02-14 | Robins Chad M (CEO and Chairman) | Option Ex | 317,842 | 6.32 | 2,008,760 |
| 2025-02-13 | Robins Chad M (CEO and Chairman) | Sale | 200,574 | 8.44 | 1,692,844 |
| 2025-02-13 | Robins Chad M (CEO and Chairman) | Option Ex | 200,574 | 6.32 | 1,267,626 |
| 2024-11-18 | Piskel Kyle (Chief Financial Officer) | Sale | 248 | 4.98 | 1,235 |
| 2024-10-08 | Bobulsky Susan (Chief Commercial Officer, MRD) | Option Ex | 5,000 | 1.98 | 9,900 |
| 2024-08-22 | Taylor Stacy L (SVP and General Counsel) | Sale | 26,922 | 4.50 | 121,068 |
| 2024-03-12 | Neupert Peter M (Director) | Option Ex | 15,000 | .84 | 12,600 |
| 2024-03-05 | Peterson Tycho (Chief Financial Officer) | Sale | 15,456 | 3.44 | 53,168 |
| 2024-03-05 | Bobulsky Susan (Chief Commercial Officer, MRD) | Sale | 12,991 | 3.44 | 44,624 |
| 2024-03-05 | Taylor Stacy L (SVP and General Counsel) | Sale | 13,381 | 3.44 | 45,963 |
| 2024-03-05 | Benzeno Sharon (Chief Commercial Ofc Imm Med) | Sale | 29,390 | 3.44 | 100,954 |
| 2024-03-05 | Rubinstein Julie (President) | Sale | 39,070 | 3.50 | 136,549 |
| 2024-03-05 | Piskel Kyle (Principal Accounting Officer) | Sale | 7,727 | 3.43 | 26,503 |
| 2024-03-05 | Lo Francis (Chief People Officer) | Sale | 14,700 | 3.44 | 50,494 |
| 2024-03-05 | Robins Chad M (CEO and Chairman) | Sale | 48,673 | 3.44 | 167,191 |
| 2023-12-13 | Neupert Peter M (Director) | Option Ex | 100,000 | .84 | 84,000 |
| 2023-11-16 | Piskel Kyle (Principal Accounting Officer) | Sale | 259 | 4.13 | 1,069 |
| 2023-08-08 | Sood Nitin (Chief Commercial Officer, MRD) | Sale | 10,550 | 6.54 | 68,997 |
| 2023-08-07 | Sood Nitin (Chief Commercial Officer, MRD) | Sale | 5,652 | 6.78 | 38,320 |
| 2023-06-20 | Peterson Tycho (Chief Financial Officer) | Sale | 134,961 | 8.14 | 1,098,582 |
| 2023-06-20 | Peterson Tycho (Chief Financial Officer) | Option Ex | 134,961 | 7.30 | 985,215 |
| 2023-06-15 | Peterson Tycho (Chief Financial Officer) | Sale | 70,000 | 8.53 | 597,100 |
| 2023-06-15 | Peterson Tycho (Chief Financial Officer) | Option Ex | 14,328 | 7.30 | 104,594 |
| 2023-06-02 | Peterson Tycho (Chief Financial Officer) | Sale | 38,000 | 7.16 | 272,080 |
| 2023-04-11 | Adams R Mark (Chief Operating Officer) | Sale | 2,308 | 8.63 | 19,918 |
| 2023-04-10 | Adams R Mark (Chief Operating Officer) | Sale | 817 | 8.50 | 6,944 |
| 2023-03-27 | Griffin Michelle Renee (Director) | Sale | 2,341 | 8.49 | 19,877 |
| 2023-03-07 | Sood Nitin (Chief Commercial Officer, MRD) | Sale | 9,813 | 8.60 | 84,391 |
| 2023-03-07 | Adams R Mark (Chief Operating Officer) | Sale | 17,155 | 8.60 | 147,533 |
| 2023-03-07 | Taylor Stacy L (SVP and General Counsel) | Sale | 13,387 | 8.60 | 115,128 |
| 2023-03-06 | Sood Nitin (Chief Commercial Officer, MRD) | Sale | 6,661 | 8.57 | 57,084 |
| 2023-03-06 | Adams R Mark (Chief Operating Officer) | Sale | 6,529 | 8.57 | 55,953 |
| 2023-03-06 | Taylor Stacy L (SVP and General Counsel) | Sale | 5,491 | 8.57 | 47,057 |
| 2023-03-06 | Benzeno Sharon (Chief Commercial Ofc Imm Med) | Sale | 11,749 | 8.57 | 100,688 |
| 2023-03-06 | Rubinstein Julie (President) | Sale | 22,668 | 8.57 | 194,264 |
| 2023-03-06 | Piskel Kyle (Principal Accounting Officer) | Sale | 3,529 | 8.57 | 30,261 |
| 2023-03-06 | Lo Francis (Chief People Officer) | Sale | 6,816 | 8.57 | 58,413 |
| 2023-02-02 | Hershberg Robert (Director) | Option Ex | 53,000 | .45 | 23,850 |
| 2023-01-10 | Adams R Mark (Chief Operating Officer) | Sale | 2,130 | 8.58 | 18,275 |
| 2023-01-09 | Adams R Mark (Chief Operating Officer) | Sale | 995 | 8.50 | 8,457 |
| 2022-11-16 | Piskel Kyle (Principal Accounting Officer) | Sale | 959 | 8.87 | 8,506 |
| 2022-11-01 | Sood Nitin (Chief Commercial Officer, MRD) | Sale | 31,066 | 8.00 | 248,528 |
| 2022-10-10 | Adams R Mark (Chief Operating Officer) | Sale | 2,284 | 7.13 | 16,284 |
| 2022-10-07 | Adams R Mark (Chief Operating Officer) | Sale | 841 | 7.61 | 6,400 |
| 2022-08-05 | Sood Nitin (Chief Commercial Officer, MRD) | Sale | 17,540 | 10.98 | 192,589 |
| 2022-07-08 | Adams R Mark (Chief Operating Officer) | Sale | 2,300 | 10.47 | 24,081 |
| 2022-07-07 | Adams R Mark (Chief Operating Officer) | Sale | 825 | 9.53 | 7,862 |
| 2022-04-07 | Adams R Mark (Chief Operating Officer) | Sale | 831 | 13.17 | 10,944 |
| 2022-03-09 | Robins Chad M (CEO and Chairman) | Sale | 14,815 | 12.46 | 184,594 |
| 2022-03-09 | Robins Chad M (CEO and Chairman) | Option Ex | 14,815 | 6.32 | 93,630 |
| 2022-03-08 | Taylor Stacy L (SVP and General Counsel) | Sale | 2,387 | 11.44 | 27,307 |
| 2022-03-08 | Baldo Lance (Chief Medical Officer) | Sale | 3,350 | 11.43 | 38,290 |
| 2022-03-08 | Lo Francis (Chief People Officer) | Sale | 3,582 | 11.44 | 40,978 |
| 2022-03-08 | Robins Chad M (CEO and Chairman) | Sale | 14,815 | 11.38 | 168,594 |
| 2022-03-08 | Robins Chad M (CEO and Chairman) | Option Ex | 14,815 | 6.32 | 93,630 |
| 2022-03-07 | Adams R Mark (Chief Operating Officer) | Sale | 1,244 | 12.01 | 14,940 |
| 2022-03-07 | Taylor Stacy L (SVP and General Counsel) | Sale | 1,569 | 12.01 | 18,843 |
| 2022-03-07 | Benzeno Sharon (Chief Business Development Officer) | Sale | 2,670 | 12.01 | 32,066 |
| 2022-03-07 | Robins Harlan S (Chief Scientific Officer) | Sale | 4,517 | 12.01 | 54,249 |
| 2022-03-07 | Baldo Lance (Chief Medical Officer) | Sale | 2,373 | 12.01 | 28,499 |
| 2022-03-07 | Rubinstein Julie (President) | Sale | 4,613 | 12.01 | 55,402 |
| 2022-03-07 | Piskel Kyle (Principal Accounting Officer) | Sale | 220 | 12.01 | 2,642 |
| 2022-03-07 | Lo Francis (Chief People Officer) | Sale | 1,569 | 12.01 | 18,843 |
| 2022-03-07 | Robins Chad M (CEO and Chairman) | Sale | 19,239 | 11.94 | 229,060 |
| 2022-03-07 | Robins Chad M (CEO and Chairman) | Option Ex | 14,815 | 6.32 | 93,630 |
| 2022-01-07 | Adams R Mark (Chief Operating Officer) | Sale | 1,021 | 23.32 | 23,809 |
| 2021-12-22 | Taylor Stacy L (SVP and General Counsel) | Sale | 15,338 | 30.00 | 460,140 |
| 2021-12-22 | Taylor Stacy L (SVP and General Counsel) | Option Ex | 15,338 | 7.17 | 110,050 |
| 2021-12-22 | Cohen Chad M (Chief Financial Officer) | Sale | 10,000 | 30.00 | 300,000 |
| 2021-12-22 | Cohen Chad M (Chief Financial Officer) | Option Ex | 10,000 | 7.27 | 72,700 |
| 2021-11-18 | Robins Harlan S (Chief Scientific Officer) | Sale | 300 | 31.36 | 9,408 |
| 2021-11-18 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 300 | 6.55 | 1,965 |
| 2021-11-17 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,700 | 32.05 | 118,584 |
| 2021-11-17 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,700 | 6.55 | 24,235 |
| 2021-11-10 | Cohen Chad M (Chief Financial Officer) | Sale | 5,000 | 33.93 | 169,650 |
| 2021-11-10 | Cohen Chad M (Chief Financial Officer) | Option Ex | 5,000 | 7.27 | 36,350 |
| 2021-11-09 | Cohen Chad M (Chief Financial Officer) | Sale | 5,000 | 36.03 | 180,150 |
| 2021-11-09 | Cohen Chad M (Chief Financial Officer) | Option Ex | 5,000 | 7.27 | 36,350 |
| 2021-10-21 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,700 | 33.73 | 124,800 |
| 2021-10-21 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,700 | 6.55 | 24,235 |
| 2021-10-20 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,700 | 33.71 | 124,727 |
| 2021-10-20 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,700 | 6.55 | 24,235 |
| 2021-10-19 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,800 | 33.34 | 126,673 |
| 2021-10-19 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,800 | 6.55 | 24,890 |
| 2021-10-08 | Adams R Mark (Chief Operating Officer) | Sale | 1,801 | 33.67 | 60,639 |
| 2021-10-08 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 32.96 | 128,379 |
| 2021-10-08 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
| 2021-10-07 | Adams R Mark (Chief Operating Officer) | Sale | 1,324 | 32.47 | 42,990 |
| 2021-10-07 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 33.09 | 128,885 |
| 2021-10-07 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
| 2021-10-06 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 32.27 | 125,691 |
| 2021-10-06 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
| 2021-10-06 | Cohen Chad M (Chief Financial Officer) | Sale | 5,000 | 32.30 | 161,500 |
| 2021-10-06 | Cohen Chad M (Chief Financial Officer) | Option Ex | 5,000 | 7.27 | 36,350 |
| 2021-10-05 | Cohen Chad M (Chief Financial Officer) | Sale | 5,000 | 32.51 | 162,550 |
| 2021-10-05 | Cohen Chad M (Chief Financial Officer) | Option Ex | 5,000 | 7.27 | 36,350 |
| 2021-09-15 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 36.88 | 143,628 |
| 2021-09-15 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
| 2021-09-14 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 36.92 | 143,822 |
| 2021-09-14 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
| 2021-09-13 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 37.64 | 146,607 |
| 2021-09-13 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
| 2021-09-10 | Robins Chad M (CEO and Chairman) | Sale | 5,000 | 38.73 | 193,649 |
| 2021-09-09 | Robins Chad M (CEO and Chairman) | Sale | 24,753 | 38.42 | 951,010 |
| 2021-09-08 | Robins Chad M (CEO and Chairman) | Sale | 13,746 | 38.73 | 532,313 |
| 2021-09-08 | Cohen Chad M (Chief Financial Officer) | Sale | 5,000 | 39.01 | 195,050 |
| 2021-09-08 | Cohen Chad M (Chief Financial Officer) | Option Ex | 5,000 | 7.27 | 36,350 |
| 2021-09-07 | Taylor Stacy L (SVP and General Counsel) | Sale | 495 | 40.00 | 19,800 |
| 2021-09-07 | Taylor Stacy L (SVP and General Counsel) | Option Ex | 495 | 6.55 | 3,242 |
| 2021-09-07 | Cohen Chad M (Chief Financial Officer) | Sale | 9,375 | 39.71 | 372,281 |
| 2021-09-07 | Cohen Chad M (Chief Financial Officer) | Option Ex | 9,375 | 6.55 | 61,406 |
| 2021-08-27 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 34.58 | 134,669 |
| 2021-08-27 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
| 2021-08-27 | Griffin Michelle Renee (Director) | Sale | 14,916 | 35.00 | 522,060 |
| 2021-08-27 | Griffin Michelle Renee (Director) | Option Ex | 14,916 | 7.80 | 116,344 |
| 2021-08-26 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 33.89 | 132,001 |
| 2021-08-26 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
| 2021-08-25 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 34.09 | 132,780 |
| 2021-08-25 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
| 2021-08-11 | Cohen Chad M (Chief Financial Officer) | Sale | 10,000 | 33.98 | 339,750 |
| 2021-08-11 | Cohen Chad M (Chief Financial Officer) | Option Ex | 10,000 | 6.55 | 65,500 |
| 2021-08-10 | Cohen Chad M (Chief Financial Officer) | Sale | 5,000 | 35.00 | 175,000 |
| 2021-08-10 | Cohen Chad M (Chief Financial Officer) | Option Ex | 5,000 | 6.55 | 32,750 |
| 2021-07-21 | Robins Harlan S (Chief Scientific Officer) | Sale | 3,895 | 37.70 | 146,841 |
| 2021-07-21 | Robins Harlan S (Chief Scientific Officer) | Option Ex | 3,895 | 6.32 | 24,616 |
Insider trading activities including stock purchases, stock sales, and option exercises of ADPT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Adaptive Biotechnologies Corp (symbol ADPT, CIK number 1478320) see the Securities and Exchange Commission (SEC) website.